Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (Covovax(TM)) after homologous and heterologous two-dose regimens

OBJECTIVES: To report the safety and immunogenicity profile of a protein subunit vaccine (Covovax(TM)) given as a third (booster) dose to individuals primed with different primary vaccine regimens. METHODS: A third dose was administered to individuals with an interval range of 3-10 months after the...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanokudom, Sitthichai, Chansaenroj, Jira, Suntronwong, Nungruthai, Assawakosri, Suvichada, Yorsaeng, Ritthideach, Nilyanimit, Pornjarim, Aeemjinda, Ratchadawan, Khanarat, Nongkanok, Vichaiwattana, Preeyaporn, Klinfueng, Sirapa, Thongmee, Thanunrat, Katanyutanon, Apirat, Thanasopon, Wichai, Arayapong, Jirawan, Withaksabut, Withak, Srimuan, Donchida, Thatsanatorn, Thaksaporn, Sudhinaraset, Natthinee, Wanlapakorn, Nasamon, Honsawek, Sittisak, Poovorawan, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678824/
https://www.ncbi.nlm.nih.gov/pubmed/36427701
http://dx.doi.org/10.1016/j.ijid.2022.11.022

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678824/
https://www.ncbi.nlm.nih.gov/pubmed/36427701
http://dx.doi.org/10.1016/j.ijid.2022.11.022

Ejemplares similares